TheCryptoChartWhisperer

TCON 15Min Scalpers edition

Long
NASDAQ:TCON   TRACON Pharmaceuticals, Inc
test
TRACON Pharmaceuticals , Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Comment:
$1.93 BUY
Comment:
Reaffirmation into $31 target
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.